70
Participants
Start Date
September 15, 2025
Primary Completion Date
June 30, 2029
Study Completion Date
June 30, 2029
Durvalumab
Durvalumab (IV) every 4 weeks until a maximum of 24 months.
NOT_YET_RECRUITING
Research Site, Jerez de la Frontera
RECRUITING
Research Site, A Coruña
RECRUITING
Research Site, Madrid
RECRUITING
Research Site, Madrid
RECRUITING
Research Site, Málaga
NOT_YET_RECRUITING
Research Site, Oviedo
NOT_YET_RECRUITING
Research Site, Santander
NOT_YET_RECRUITING
Research Site, Seville
RECRUITING
Research Site, Valencia
RECRUITING
Research Site, Barakaldo
RECRUITING
Research Site, Zaragoza
RECRUITING
Research Site, Badajoz
NOT_YET_RECRUITING
Research Site, Barcelona
NOT_YET_RECRUITING
Research Site, Barcelona
NOT_YET_RECRUITING
Research Site, Barcelona
Lead Sponsor
AstraZeneca
INDUSTRY